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Background: Breast cancer metastasis suppressor 1 (BRMS1) is a metastasis suppressor gene. This study aimed to
investigate the impact of BRMS1 on metastasis in nasopharyngeal carcinoma (NPC) and to evaluate the prognostic
significance of BRMS1 in NPC patients.
Methods: BRMS1 expression was examined in NPC cell lines using quantitative reverse transcription-polymerase
chain reaction and Western blotting. NPC cells stably expressing BRMS1 were used to perform wound healing and
invasion assays in vitro and a murine xenograft assay in vivo. Immunohistochemical staining was performed in 274
paraffin-embedded NPC specimens divided into a training set (n = 120) and a testing set (n = 154).
Results: BRMS1 expression was down-regulated in NPC cell lines. Overexpression of BRMS1 significantly reversed
the metastatic phenotype of NPC cells in vitro and in vivo. Importantly, low BRMS1 expression was associated with
poor distant metastasis-free survival (DMFS, P< 0.001) and poor overall survival (OS, P< 0.001) in the training set;
these results were validated in the testing set and overall patient population. Cox regression analysis demonstrated
that low BRMS1 expression was an independent prognostic factor for DMFS and OS in NPC.
Conclusions: Low expression of the metastasis suppressor BRMS1 may be an independent prognostic factor for
poor prognosis in NPC patients.
Keyword: BRMS1, Nasopharyngeal carcinoma, Metastasis, PrognosisBackground
According to the Global Cancer Statistics released by
the International Agency for Research on Cancer
(IARC), there were an estimated 84,400 incident cases of
nasopharyngeal carcinoma (NPC) and 51,600 NPC-
related deaths in 2008 [1]. Highly metastatic NPC is one
of the most common malignant tumors in southern
China, especially in the province of Guangdong, [2]. For
patients with locally advanced disease receiving chemor-
adiation therapy, the rate of distant metastasis may* Correspondence: wanghyun@mail.sysu.edu.cn; majun2@mail.sysu.edu.cn
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reproduction in any medium, provided the orrange between 13 and 21% [3,4]. Studies by our group
and others have shown that although the increasingly
prevalent use of intensity-modulated radiation therapy
(IMRT) and concurrent chemoradiation therapy for
locoregionally advanced NPC has improved local and re-
gional control in NPC, distant metastasis has become a
predominant pattern of treatment failure in NPC
patients who do not present metastases at diagnosis
[5,6].
Metastasis is a multistep process in which cancer cells
disseminate and establish secondary tumors at sites distant
from the primary tumor; metastasis is estimated to be re-
sponsible for approximately 90% of all cancer deaths [7].
The breast cancer metastasis suppressor 1 (BRMS1) gene
was originally identified as a true metastasis suppressor
gene in breast cancer cell lines as stable overexpression of
BRMS1 suppressed pulmonary metastasis but did not. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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demonstrated that BRMS1 dramatically suppresses the
metastatic phenotype in vitro in cells from several other-
types of cancer, including melanoma [9,10], ovarian cancer
[11], bladder cancer [12] and lung cancer [13]. BRMS1 was
also shown to inhibit metastasis in xenograft models of
breast cancer [8], melanoma [9] and ovarian carcinoma [11].
However, there are no published reports on in vitro or
in vivo BRMS1 expression and function in NPC and no
available articles that address a possible relationship between
BRMS1 expression and clinical outcomes in NPC.
In this study, we aimed to examine BRMS1 expression
and functional status in vitro and in vivo and to explore
its clinical significance in clinical NPC specimens. The
results may help to understand the mechanisms of me-
tastasis in NPC and provide information for develop-




Results of qRT-PCR and Western blotting indicated that
BRMS1 expression was low in NPC cells. Therefore we
created cell lines stably overexpressing BRMS1 or the
corresponding empty vector. The effect of BRMS1 on
migration and invasion was observed in artificial wound
healing assay, transwell invasion array in vitro. A murine
model of NPC was constructed to further investigate the
metastasis-inhibiting effects of BRMS1 compared with
vector (n = 8 per group). To determine the clinical sig-
nificance of BRMS1 in NPC patients, we detected
BRMS1 expression by immunohistochemistry in 274
tumor specimens which were randomly divided into a
training set (n = 120) and a testing set (n = 154). The as-
sociation between BRMS1 expression and patient out-
comes was explored in the training set and then validated
in the testing set and overall patient population.
Cell lines and cell culture
The NPC cell lines (SUNE-1, CNE-1, C666-1, CNE-2
and HNE-1) and the immortalized nasopharyngeal epi-
thelial cell line (NP69) were the kind gifts of Professor
Zeng Mu-sheng at Sun Yat-sen University Cancer Center
(SYSUCC). All NPC cell lines were maintained in RPMI
1640 (Invitrogen, Beijing, China) supplemented with
10% fetal bovine serum (Gibco, Montevideo, Uruguay),
while the NP69 cells were cultured in Keratinocyte-SFM
(Invitrogen, Auckland, NZ) supplemented with bovine
pituitary extract, as previously described [14]. All the cell
lines were incubated at 37°C in a 5% CO2 incubator.
RNA extraction and qRT-PCR
The total RNA was extracted from the cell lines using
TRIzol reagent (Life Technologies, Grand Island, NY).The first-strand cDNA was synthesized using the M-MLV
First-strand Synthesis Kit (Invitrogen, China). The following
PCR primers were used for BRMS1 and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH): BRMS1 forward,
50-AAGGCACCTCTGGTTTCTGG-30; BRMS1 reverse,
50-TGTGAACAGCAGGGTCAAGGT-30; GAPDH forward,
50-CTCCTCCTGTTCG ACAGTCAGC-30 and GAPDH re-
verse, 50-CCCAATACGACCAAATCCGTT-30. The quanti-
tative PCR was performed using SYBR Green qPCR
SuperMix-UDG reagent (Invitrogen, China) and an ABI
PRISM 7900HT sequence detection system (Applied Bio-
systems, USA). The BRMS1 cycle threshold (Ct) was nor-
malized to the GAPDH internal reference.
Western blotting
The protein was extracted as previously described [14] ,
loaded onto 12% SDS-PAGE gels and transferred to
PVDF membranes. The membranes were blocked with a
mouse anti-human BRMS1 antibody (1:500; Abnova,
Taipei, Taiwan). BRMS1 expression was detected with
horseradish peroxidase-conjugated goat anti-mouse anti-
body (1:10,000, Merck, Darmstadt, Germany) and a
Super Signal enhanced chemiluminescence substrate
(Pierce, Rockford, IL, USA). A rabbit anti-human α-
tubulin antibody (1:1000, CST, USA) was used to con-
firm equal loading.
Establishing NPC cells that stably expressed BRMS1
Following the manufacturer’s instructions, the CNE-2
and SUNE-1 cell lines were stably transfected using a
Lenti-Pac™ HIV Expression Packaging Kit (GeneCopoeia,
Rockville, MD, USA) and a plasmid encoding BRMS1 or
a control vector plasmid. Briefly, EndoFectin Lenti re-
agent was used to transfect the parental CNE-2 and
SUNE-1 cells with 2.5 μg of either a lentiviral BRMS1
ORF plasmid (EX-V1241-Lv105, GeneCopoeia) or a con-
trol vector plasmid (EX-NEG-Lv105, GeneCopoeia). The
cells were allowed to grow under puromycin (0.5 μg/ml)
selection for 10 days. Western blotting and qRT-PCR
were used to analyze the BRMS1 expression. The cells
overexpressing BRMS1 were renamed CNE-2B and
SUNE-1B, and the vector control cells were renamed
CNE-2V and SUNE-1V.
Wound healing assay
The CNE-2B/V and SUNE-1B/V cells were seeded in
6-well cell culture plates. When the cell confluence
reached approximately 90%, the cells were serum-
starved for 24 h, and wounds were then created by
scraping the cell monolayer with a 200-μl pipette tip.
The cells were then rinsed with serum-free medium to
remove floating cells and debris. The culture plates were
incubated at 37°C. The width of the wounds was mea-
sured at various times. Representative wounds were
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scope (4× objective, Leica, Wetzlar, Germany). The ex-
periment was repeated three times.
Transwell invasion assays
The log phase CNE-2B/V and SUNE-1B/V cells were
trypsinized and suspended in single cell solutions. A
total of 1 × 105 cells in 200 μl serum-free RPMI 1640
medium were seeded on 8-μm-pore polycarbonate mem-
brane chambers in Transwell plates (Corning, Corning,
NY, USA) that were coated Matrigel (BD Biosciences,
San Jose, CA), and 600 μl of RPMI 1640 containing 20%
FBS was added to the lower chamber. After incubation
for 18 hours at 37°C in a 5% CO2 incubator, the cells on
the top insert surface were removed by wiping with a
cotton swab. The cells that had invaded to the bottom
surface of the insert were fixed with a 3:1 mixture of
methanol and acetic acid for 10 minutes, stained in 0.5%
crystal violet for 30 minutes, rinsed in PBS and then
subjected to microscopic inspection (200×). The num-
bers of invading cells were obtained by counting the
number of cells in five random microscopic fields per
membrane. The experiment was repeated three times.
In vivo lung metastasis model
Male BALB/c nude mice between 5 and 6 weeks old
were purchased from the Hunan Slac Jingda Laboratory
Animal Co., Ltd. (Changsha, Hunan province, China)
and were in quarantined for a week before treatment.
Animals were provided with standard laboratory chow
and tap water ad libitum under special pathogen free
(SPF) conditions. All the animal studies were conducted
in accordance with "Animal Research: Reporting In Vivo
Experiments" (ARRIVE) guidelines and the guidelines of
Institutional Animal Care and Use Committee at SYSUCC.
All mice were treated humanely throughout the experimen-
tal period.
To assay for lung metastases, 1× 106 SUNE-1B/V cells
in 200 μl PBS were injected into the lateral tail veins of
the mice (n =8 per group). Nine weeks later, the mice
were necropsied after anesthesia. The lungs of mice were
fixed in 3.7% formaldehyde, 5% glacial acetic acid, and
72% ethanol for at least one day before proceeding to
paraffin embedding. Serial 5-μm sections were cut, and
one of every ten slides was stained with H&E for histo-
pathological examination.
Tissue specimens, patient information and follow-up
274 biopsy-proven and non-distant-metastasis paraffin-
embedded NPC samples and 8 noncancerous nasopha-
ryngeal (NNP) tissues were collected at SYSUCC be-
tween April 2003 and December 2006. None of the NPC
patients received any therapies before biopsies. Prior
informed consents from the patients and approval fromthe medical ethics committee of SYSUCC were obtained.
The patients’ clinical information is summarized in
Table 1. The clinical staging of all the NPC patients was
re-performed according to the 7th International Union
Against Cancer (UICC)/American Joint Committee on
Cancer (AJCC) system [15]. The 274 NPC FFPE speci-
mens were randomly divided into a training set and a
testing set using a random number table generated by
SPSS 16.0 software (SPSS, Chicago, IL, USA).
After completing their therapy, the patients returned
for follow-up appointments every 3 months for the first
2 years and every 6 months thereafter. The last follow-
up date was April 30, 2011, and the median follow-up
period was 61.9 months (range, 3.1-85.4 months). All
the events were measured from the date of diagnosis.
The following end points were assessed (as the time to
the defining event): distant metastasis-free survival
(DMFS, with “distant” defined as metastasis to other
organs or tissues) and overall survival (OS, with “overall”
defined as death due to any cause).Immunohistochemistry
Immunohistochemical staining was performed similarly
to previous report [14]. The Mouse anti-BRMS1 anti-
body (1:400; Abnova, Taiwan) and biotinylated anti-
mouse secondary antibody (zsbio, Beijing, China) were
used. The degree of immunostaining was reviewed and
scored independently by two pathologists. The staining
intensity was scored as 0 (negative), 1 (weak), 2
(medium), and 3 (strong). Extent of staining was scored
as 0 (0%), 1 (1% to 25%), 2 (26% to 50%), 3 (51% to
75%), and 4 (76 to 100%) according to the percentages
of positive tumor cells in the tumor area. The final stain-
ing score was the sum of the intensity and extent score
[16].Statistical analysis
The data were expressed as the mean ± SD. An
independent-sample T test was used to test for signifi-
cant differences between continuous variables. The dis-
tributions of the NPC patients’ clinical parameters were
compared between the high and low BRMS1 expression
groups using the chi-square or Fisher’s exact tests.
Kaplan-Meier survival analysis was used to compare the
patient survival times. The log-rank test was used to
evaluate the differences in survival probabilities between
the groups. A Cox proportional hazards regression ana-
lysis with backward stepwise selection was used to ex-
plore the independent predictive factors for DMFS and
OS. All the quoted p values are two-sided, and P < 0.05
was considered to be statistically significant. The statis-
tical analyses were performed using SPSS 16.0 (SPSS,
Chicago, IL).
Table 1 The correlations between BRMS1 expression and the clinicopathological characteristics of nasopharyngeal carcinoma
Characteristic Training set (n=120) Testing set (n=154) Overall patients (n=274)
low high P* low high P* low high P*
expression expression expression expression expression expression
no. (%) no. (%) no. (%) no. (%) no. (%) no. (%)
Gender
Male 28 (66.7) 60 (76.9) 0.226 44 (77.2) 74 (76.3) 0.898 72 (72.7) 134 (76.6) 0.286
Female 14 (33.3) 18 (23.1) 13 (22.8) 23 (23.7) 27 (27.3) 41 (23.4)
Age (years)
≤ 46 20 (47.6) 37 (47.4) 0.985 31 (54.4) 49 (50.5) 0.643 51 (51.5) 86 (49.1) 0.401
> 46 22 (52.4) 41 (52.6) 26 (45.6) 48 (49.5) 48 (49.5) 89 (50.9)
WHO type
Type III 40 (95.2) 74 (94.9) 1.000 56 (98.2) 94 (96.9) 1.000 96 (97.0) 168 (96.0) 0.482
Other type 2 (4.8) 4 (5.1) 1 (1.8) 3 (3.1) 3 (3.0) 7 (4.0)
VCA-IgA
≥ 1:320 23(54.8) 41(52.6) 0.818 28(49.1) 48(49.5) 0.965 51(51.5) 89(50.9) 0.917
< 1:320 19(45.2) 37(47.4) 29(50.9) 49(50.5) 48(48.5) 86(49.1)
EA-IgA
≥ 1:20 20(47.6) 43(55.1) 0.432 33(57.9) 50(51.5) 0.445 53(53.5) 93(53.1) 0.950
< 1:20 22(52.4) 35(44.9) 24(42.1) 47(48.5) 46(46.7) 82(46.9)
AER
≥ 63% 8(19.0) 23(29.5) 0.213 17(29.8) 26(26.8) 0.687 25(25.3) 49(28.0) 0.623
< 63% 34(81.0) 55(70.5) 40(70.2) 71(73.2) 74(74.7) 126(72.0)
UICC 7th T stage
T1 5 (11.9) 16 (20.5) 0.470 11 (19.3) 18 (18.6) 0.996 16 (16.2) 34 (19.4) 0.853
T2 17 (40.5) 22 (28.2) 18 (31.6) 32 (33.0) 35 (35.4) 54 (30.9)
T3 9 (21.4) 19 (24.4) 16 (28.1) 26 (26.8) 25 (25.3) 45 (25.5)
T4 11 (26.2) 21 (26.9) 12 (21.1) 21 (21.6) 23 (23.2) 42 (23.7)
UICC 7th N stage
N0 4 (9.5) 14 (17.9) 0.644 8 (14.0) 14 (14.4) 0.837 12 (12.1) 28 (16.0) 0.732
N1 22 (52.4) 36 (46.2) 24 (42.1) 47 (48.5) 46 (46.5) 83 (47.4)
N2 10 (23.8) 16 (20.5) 15 (26.3) 20 (20.6) 25 (25.3) 36 (20.6)


















Table 1 The correlations between BRMS1 expression and the clinicopathological characteristics of nasopharyngeal carcinoma (Continued)
No 4 (9.5) 14 (17.9) 0.307 8 (14.0) 14 (14.4) 0.806 12 (12.1) 28 (16.0) 0.382
Yes 38 (90.5) 64 (82.1) 49 (86.0) 83 (85.6) 87 (87.9) 147 (84.0)
UICC 7th stage
I 0 (0.0) 4 (5.1) 0.513 1 (1.8) 3 (3.1) 0.949 8 (2.9) 8 (2.9) 0.538
II 13 (31.0) 22 (28.2) 17 (29.8) 27 (27.8) 79 (28.8) 79 (28.8)
III 13 (31.0) 22 (28.2) 19 (33.3) 31 (32.0) 85 (31.0) 85 (31.0)
IV 16 (38.0) 30 (38.5) 20 (35.1) 36 (37.1) 102 (37.2) 102 (37.2)
Distant metastasis#
No 24 (57.1) 67 (85.9) 0.000 35 (61.4) 83 (85.6) 0.000 59 (59.6) 150 (85.7) 0.000
Yes 18 (42.8) 11 (14.1) 22 (38.6) 14 (14.4) 40 (40.4) 25 (14.3)

















Figure 1 BRMS1 expression in NPC cells and tissues. Quantitative
RT-PCR (A) and western blotting analysis (B) of BRMS1 mRNA and
protein expression in parental NPC cells.. Quantitative RT-PCR analysis
of BRMS1 mRNA was normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). The quantitative RT-PCR data are
represented as the mean± SD (* p<0.01; Student’s t-test). Equal
protein loading was determined by α-tubulin in western blotting.
(C) analysis of BRMS1 protein expression in NPC and noncancerous
nasopharyngeal (NNP) tissues using immunohistochemistry ( IHC). The
NNP tissue (upper left) showed strong BRMS1 staining. The NPC
tissues showed various degrees of BRMS1 staining: weak (upper right),
moderate (lower left) and strong (lower right) (magnification, 100×).
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BRMS1 expression is decreased in NPC cells
Since BRMS1 is a metastasis suppressor in many types of
cancer, we hypothesize that NPC progression, especially
NPC metastasis, may be related to BRMS1 levels. The
results of quantitative reverse transcription-polymerase
chain reaction (qRT-PCR, Figure 1A) and western blotting
(Figure 1B) indicated that both BRMS1 mRNA and protein
were markedly decreased in the examined NPC cell lines
compared to the NP69, suggesting that low BRMS1 expres-
sion may be involved in NPC progression.
BRMS1 inhibits migration and invasion in vitro
To confirm that low BRMS1 expression may cause NPC
cell metastasis, we conducted an in vitro cell migration
and invasion assay using the CNE-2B/V and SUNE-1B/V
cell lines that stably expressed BRMS1 or an empty vector.
The qRT-PCR and western blot analyses confirmed that
BRMS1 mRNA and protein expression were greater in the
CNE-2B and SUNE-1B cells than in the corresponding
CNE-2V and SUNE-1V control cells (data not shown). The
effect of BRMS1 on NPC cell migration was then exam-
ined in the wound healing and migration assays. As shown
in Figure 2A, the wounded BRMS1-expressing cells (CNE-
2B and SUNE-1B) traveled a significantly shorter distance
after a 24 h incubation period than did the corresponding
vector control cells. In addition, a Transwell invasion assay
was conducted to explore the effects of BRMS1 on NPC
cell invasion. The results demonstrated that the invasive
abilities of the CNE-2B and SUNE-1B cells were signifi-
cantly lower than those of the corresponding vector cells,
indicating massive transmembrane invasion (P<0.01 re-
spectively, Figure 2B). These results were further quantified
by calculating the number of invading cells per field of high
magnification.
BRMS1 inhibits pulmonary metastasis in vivo
To define the function of BRMS1, a murine xenograft model
of distant NPC metastasis was constructed. Upper-left of
Figure 2C showed that there were few metastatic nodules on
the surface of excised lungs in the SUNE-1B group, whereas
there were many in the control cohort (upper-middle of
Figure -2C). This macroscopic observation is quantified in
the associated bar graphs, demonstrating a significant de-
crease in the number ofmetastatic nodules in the presence of
BRMS1 (p<0.01, upper-right of Figure -2C).
In addition, lung sections from each group were stained
with H&E to show the degree of metastasis. The results of
the hematoxylin and eosin (H&E) staining indicated sig-
nificantly fewer lung metastasis nodules in the SUNE-1B
group than in the SUNE-1V group (4.9± 3.4 vs. 20.8± 3.4,
p< 0.01, lower of Figure 2C). These results suggested that
BRMS1 expression significantly inhibited xenograft cell in-
vasion in the surrounding tissue. These results aboveindicated the metastasis-inhibiting role of BRMS1 in this
xenograft model.
BRMS1 protein expression is decreased in NPC tissues
To explore the association between BRMS1 expression and
clinical outcome in NPC patients, immunohistochemistry
Figure 2 BRMS1 inhibits NPC cell migration and invasion in vitro and suppresses lung metastasis in vivo. (A) The effect of BRMS1
overexpression on cell migration in the wound healing assay. The right panels show a slower wound healing response in the BRMS1-
overexpressing cells than in the vector control cells 24 h after scratching (magnification, 40×). (B) The effect of BRMS1 overexpression on cell
invasion in the Transwell migration assay. The left panels are representative photomicrographs (magnification, 100×), while the right panels are
the numbers of trans-membrane cells per field (magnification, 100×) counted in five random fields for each of the BRMS1-overexpressing and
control groups in triplicate parallel experiments. (* p< 0.01; Student’s t-test). (C) BRMS1 overexpression inhibits metastasis in murine NPC
xenografts. Mouse tumor xenografts were created (n = 8 per group). Representative macroscopic photographs of pulmonary metastases; the
arrowheads indicate the metastatic nodules on the surface of the lungs (upper left in C). The average numbers of metastases in each group are
shown in parallel on the right. Lung sections from each group were stained with hematoxylin and eosin (H&E) to quantify the degree of lung
metastasis (lower left in C). Histograms depicting the average number of microscopic metastases in each group are shown on the right.
(* p< 0.01; Student’s t-test).
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depicting the BRMS1 staining are shown in Figure 1C. The
BRMS1 protein expression was lower in the NPC tissues
than in the NNP tissue controls (Figure 1C).The relationship between BRMS1 expression and
clinicopathological features in NPC patients
A receiver operating characteristic (ROC) curve analysis
was used to select the cutoff scores for BRMS1 expression
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cutoff scores of BRMS1, viral capsid antigen immuno-
globulin A (VCA-IgA), early antigen immunoglobulin A
(EA-IgA) and antienzyme rate (AER) of Epstein-Barr
virus (EBV) DNase-specific neutralizing antibody for
DMFS were 4, 1:320, 1:20 and 63% respectively (Table 1,
Additional file 1: Figure S1).
The clinicopathological features of these two cohorts
and the overall patient set, including patient age and
gender, WHO pathology type, VCA, EA, AER, tumor
stage, node stage, clinical stage and metastasis, are sum-
marized and stratified according to BRMS1 expression
in Table 1. We found that in the training set, more
patients developed metastasis in the low BRMS1 expres-
sion group than in the high BRMS1 expression group
(42.8% vs. 14.1%, p < 0.001). Similar results were
observed in the testing set (38.6% vs. 14.1%, p < 0.001)
and overall patient set (40.4% vs. 14.3%, p < 0.001). NoFigure 3 Survival analysis of BRMS1 expression in the training set, te
was correlated with poor distant metastasis-free survival (upper in A) and o
validated in the testing cohort (B) and overall patient population (C). HR: h
a univariate Cox regression analysis, and the p values were calculated usingsignificant associations were found between BRMS1 ex-
pression and any of the other clinicopathological fea-
tures in any set of patients.Low BRMS1 expression is associated with poor DMFS
and OS in NPC patients
The median follow-up time for the entire patient set
was 61.8 months. The cumulative 5-year survival rate
was only 52.53% (95% confidence interval (CI), 42.69% -
62.36%) in the low BRMS1 expression group, whereas it
was 74.28% (95% CI, 65.41% - 81.87%) in the high
BRMS1 expression group. In the training set the
patients with low BRMS1 expression had poorer DMFS
(upper of Figure3A) and poorer OS (lower of Figure 3A)
than those with high BRMS1 expression (hazard ratio
(HR) 3.94, 95% CI, 1.88-8.26, p < 0.001 for DMFS; HR,
4.78, 95% CI, 2.26-10.10, p < 0.001 for OS). These resultssting set and overall patient population. (A) Low BRMS1 expression
verall survival (lower in A) in the training cohort. These results were
azard ratio; CI: confidence interval. The HR values were calculated using
the log-rank test.
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tient sets (Figure 3C).
BRMS1 is an independent prognostic factor for DMFS
and OS
A multivariate Cox regression analysis was performed to
explore the effect of various factors on DMFS and OS. Low
BRMS1 expression was indeed found to be a significant in-
dependent prognostic factor for poor DMFS (HR, 4,54,
95% CI, -2.11 – 9.76, p<0.001, Table 2) and OS (HR, 6.56,
95% CI, 2.97 – 14.41, p<0.001, Table 2) in the training set.
Similar results were also observed in the testing set (HR,
3.31, 95% CI: 1.69 – 6.47, p<0.001 for DMFS and HR, 4.39,
95% CI, 2.14– 9.01, p<0.001 for OS, Table 2) and overallTable 2 A multivariable Cox regression analysis# of BRMS1 ex
For distant metastasis free surviva
HR 95% CI
Training set
sex (men vs. women) 0.51 0.20-1.27
age (> 46 vs. ≤ 46) 1.16 0.55-2.46
WHO type (type I vs. type II) 0.89 0.20-3.99
TNM stage (III, IV vs. I, II) 3.91 1.35-11.29
BRMS1 (low vs. high) 4.54 2.11-9.76
VCA-IgA (≥ 1:320 vs. < 1:320) 0.73 0.26-2.03
EA-IgA (≥ 1:20 vs. < 1:20) 1.44 0.52-4.01
AER (≥ 63% vs. < 63%) 0.73 0.36-1.47
Testing set
sex (men vs. women) 0.56 0.22-1.38
age (> 46 vs. ≤ 46) 1.25 0.65-2.43
WHO type (type I vs. type II) 1.05 0.13-8.39
TNM stage (III, IV vs. I, II) 3.19 1.24-8.21
BRMS1 (low vs. high) 3.31 1.69-6.47
VCA-IgA (≥ 1:320 vs. < 1:320) 0.47 0.19-1.15
EA-IgA (≥ 1:20 vs. < 1:20) 2.78 1.12-6.94
AER (≥ 63% vs. < 63%) 0.57 0.26-1.29
Overall patient population
sex (men vs. women) 0.63 0.34-1.18
age (> 46 vs. ≤ 46) 1.18 0.72-1.92
WHO type (type I vs. type II) 0.90 0.28-2.91
TNM stage (III, IV vs. I, II) 3.39 1.68-6.86
BRMS1 (low vs. high) 3.59 2.17-5.92
VCA-IgA (≥ 1:320 vs. < 1:320) 0.62 0.31-1.21
EA-IgA (≥ 1:20 vs. < 1:20) 1.91 0.95-3.85
AER (≥ 63% vs. < 63%) 1.20 0.70-2.07
# The variables were selected using the backward Wald stepwise selection method
following parameters were included as covariates in each of these models: sex (me
and IV vs. I and II), BRMS1 expression (low vs. high) VCA-IgA (≥ 1:320 vs. < 1:320), E
antigenimmunoglobulin A; EA-IgA: early antigenimmunoglobulin A; AER: antienzym
HR: hazard ratio; CI: confidence interval.patient population (HR, 3.59, 95% CI, 2.17–5.92, p<0.001
for DMFS and HR, 4.77, 95% CI, 2.82–8.06 , p<0.001 for
OS, Table 2). In addition, clinical stage was found to be an
independent prognostic factor for DMFS and OS in the
training, testing and overall patient sets; AER was only an
independent prognosis factor in the overall patient popula-
tion (Table 2). These results indicated that BRMS1 is an in-
dependent prognostic factor for DMFS and OS in NPC
patients.
BRMS1 is superior to EBV biomarkers for predicting DMFS
and OS
The area under ROC curve (AUROC) of BRMS1 for pre-
dicting DMFS is bigger than that of VCA, EA and AERpression and survival in nasopharyngeal carcinoma
l For overall survival
P* HR 95% CI P*
0.15 0.29 0.11-0.79 0.11
0.54 1.11 0.53-2.35 0.72
0.80 1.31 0.26-5.02 0.81
0.01 2.59 0.99-6.83 0.04
0.00 6.56 2.97-14.41 0.00
0.93 0.41 0.15-1.13 0.21
0.76 1.80 0.66-4.92 0.88
0.35 1.51 0.74- 2.51 0.07
0.28 0.76 0.36-1.80 0.62
0.47 1.54 0.77-3.10 0.14
0.60 0.67 0.08-5.60 0.42
0.02 3.91 1.38-11.11 0.01
0.00 4.39 2.14-9.01 0.00
0.97 0.44 0.18-1.10 0.71
0.19 2.33 0.91-5.98 0.31
0.32 1.03 0.49-2.19 0.71
0.18 0.57 0.30-1.07 0.15
0.38 1.32 0.80-2.18 0.25
0.74 0.89 0.27-2.88 0.57
0.00 3.24 1.60-6.57 0.00
0.00 4.77 2.82-8.06 0.00
0.84 0.53 0.27-1.04 0.29
0.16 1.64 0.82-3.29 0.72
0.36 1.69 1.00-2.86 0.04
. * The p values were calculated using an adjusted Cox regression model. The
n vs. women), age (> 46 vs. ≤ 46), WHO type (type I vs. type II), TNM stage (III
A-IgA (≥ 1:20 vs. < 1:20) and AER (≥ 63% vs. < 63%). VCA-IgA: viral capsid
e rate (AER) of Epstein-Barr virus (EBV) DNase-specific neutralizing antibody;
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S1). Similar trends were found in the testing set and
overall patient population (data not shown). These indi-
cated that BRMS1 had a higher accuracy for predicting
DMFS than all of the tested EBV biomarkers. Moreover,
BRMS1 demonstrated a higher ability to predict OS than
VCA, EA and AER in the three cohorts (data not
shown). As described above, multivariate Cox regression
analysis indicated that BRMS1 expression was an inde-
pendent factor for both DMFS and OS in the training
set, testing set and overall patient population; however,
VCA and EA were not any prognostic value in any
group and AER was only an independent factor of OS in
the overall patient population. Therefore, BRMS1 is su-
perior to EBV biomarkers for predicting DMFS and OS.Discussion
In this study, we found low BRMS1 expression in the
NPC cell lines and tissue specimens. Artificial overex-
pression of BRMS1 in the NPC cell lines suppressed mi-
gration and invasion in vitro and inhibited the formation
of pulmonary metastases in vivo in the nude mice. Fur-
thermore, low BRMS1 expression was significantly asso-
ciated with poor DMFS and OS in the NPC patients.
These results suggested that low BRMS1 expression may
play important roles in NPC metastatic process. To our
knowledge, this is the first study to reveal a correlation
between BRMS1 expression and clinical metastasis and
survival in NPC patients.
BRMS1 has previously been demonstrated to be a
metastasis-suppressing gene in breast cancer [18,19], mel-
anoma [10,20], ovarian cancer [11], bladder cancer [12]
and lung cancer [13,21]. Low BRMS1 expression levels
have been detected in cell lines [8,9,11-13,22] and tissue
specimens [11,13,19] from various human cancers. Our
study found that BRMS1 expression levels were markedly
lower in the NPC cell lines and tissues than in the NP69
and NNP tissues, indicating that downregulation of
BRMS1 may play an important role in NPC progression.
To explore the effect of BRMS1 on NPC metastasis, we
firstly created NPC cell lines that stably expressed BRMS1
or an empty vector. Increased BRMS1 expression was
shown to decrease NPC cells migration and invasiveness
in vitro compared to the corresponding control vector. To
further define the metastasis-suppressing function of
BRMS1, a nude mouse model of NPC metastasis was con-
structed. The macroscopic and microscopic observations
of the metastatic mouse lung nodules indicated that
BRMS1 significantly suppressed pulmonary metastasis for-
mation in vivo. All of the functional studies above demon-
strate the inhibitory effects of BRMS1 on NPC metastasis,
which is consistent with reports on its effects in other can-
cers. In breast cancer, BRMS1 expression was higher inthe neo11/435 metastasis-suppressed hybrid cell line than
in the MDA-MB-435 parental line, which is a highly meta-
static breast cancer cell line in vitro. In vivo, ectopic
BRMS1-expressing MDA-MB-435 cells showed signifi-
cantly decreased incidence and number of lung and re-
gional lymph node metastases when the cells were
orthotopically injected [8]. BRMS1 expression has also
been shown to be lower in a highly metastatic human
bladder carcinoma cell line (T24T) than in the less meta-
static T24 parental cell line. In vivo modeling found that
mice inoculated with T24T cells had significantly more
metastases than mice inoculated with T24 cells [12]. Simi-
lar results were obtained for lung cancer [13], ovarian can-
cer [9] and melanoma [10,20].
In this study, we further investigated the clinical sig-
nificance of BRMS1 in NPC patients using immunohis-
tochemistry (IHC) to assay BRMS1 expression in 274
NPC tissue specimens. BRMS1 was hypothesized to be
associated with lymph node metastasis, which is usually
correlated with distant metastasis. In our study, however,
BRMS1 expression did not correlate with nodal status
(Table 1). This result was consistent with previous breast
[19,23] and lung cancer [13] studies and may imply that
BRMS1 plays different roles in lymph node and distant
metastases. Li et al. demonstrated that BRMS1 inhibits
blood vessel formation in nude mice [10] by regulating
ING4 [24]. As expected, the patients with low BRMS1
expression experienced more metastasis during the
follow-up period compared to those with high BRMS1
expression, suggesting that BRMS1 can suppress cancer
metastasis in NPC patients. Our results were consistent
with those obtained for other neoplasms, such as breast
cancer [25], melanoma [10] and NSCLC [13]. However,
there is some disagreement on the role of BRMS1 in
cancer. Lombardi et al. found that higher BRMS1 mRNA
expression was associated with poor disease-free and
overall survival [26], which is inconsistent with the
results of other studies.
In our study, a multivariate Cox regression analysis
demonstrated that both TNM stage and BRMS1 expres-
sion were independent prognostic factors for DMFS and
OS in the training set, and this conclusion was validated
in the testing and overall patient sets. Currently, the
current TNM staging system is useful for predicting
NPC outcome [15]. However, patients with identical dis-
ease stages who receive similar treatments often display
considerable variability in their clinical outcomes, indi-
cating that the TNM stage is still far from a perfect pre-
dictor. EBV biomarkers such as VCA, EA and AER have
been widely used in the diagnosis of NPC, but are not
appropriate in predicting prognosis. In our study,
BRMS1 expression was an independent prognostic factor
for both DMFS and OS in the training set, testing set
and overall patient population, while VCA and EA had
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independent factor of OS in the overall patient popula-
tion. Therefore, BRMS1 levels used in conjunction with
the TNM staging system have the potential to more
effectively predict patient metastasis potential and prog-
nosis and could guide the development of more persona-
lized therapies for this disease.
Although the clinical significance of BRMS1 in many
cancers has been established, the mechanisms by which
BRMS1 expression is decreased in tumors is still not clear.
Some studies have shown that the BRMS1 promoter is
methylated in many cancers, which might contribute to
low BRMS1 expression. Metge et al. discovered a CpG is-
land (−3477 to −2214) in the BRMS1 promoter which is
hypermethylated across several breast cancer cell lines
[27]. Another study demonstrated BRMS1 promoter
methylation of in lung cancer [21]. A recent study showed
that phosphorylation of RelA/p65 promotes DNMT-1 re-
cruitment to chromatin following BRMS1 promoter
methylation and transcriptional repression [22]. BRMS1
has also been reported to interact with the mSin3 chroma-
tin remodeling complex and to recruit histone deacety-
lases to suppress downstream gene expression [28]. It has
been shown that BRMS1 physically interacts with the
RelA/p65 subunit of NF-kB and inhibits IkBa phosphoryl-
ation, thus negatively regulating the NF-kB pathway
[29,30]. Several metastasis-related genes, such as epider-
mal growth factor receptor [31] and osteopontin [32],
have been reported to be regulated by BRMS1.
Conclusion
In summary, this is the first study to demonstrate that
reduced BRMS1 expression is associated with metastasis
and survival in NPC patients. We found that BRMS1 sup-
pressed NPC metastasis in vitro and in vivo. A survival
analysis showed that BRMS1 expression was an independ-
ent predictive factor for DMFS and OS in NPC patients.
And BRMS1 was better than EBV biomarkers in predict-
ing DMFS and OS. The results of this study suggest that
BRMS1 is a potential biomarker for metastasis and prog-
nosis in NPC patients and may provide a basis for devel-
oping gene therapy to prevent or treat NPC metastasis.
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